Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 5/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4023627 | 0.91 | KDM2B (0.39) | KDM2BDRD4HTTKMT2AKAT6A | |
| SCHEMBL4023629 | 0.91 | KDM2B (0.39) | KDM2BDRD4HTTKMT2AKAT6A | |
| SCHEMBL4022127 | 0.91 | KDM2B (0.39) | KDM2BDRD4HTTKMT2AKAT6A | |
| SCHEMBL13721312 | 0.91 | KDM2B (0.39) | KDM2BDRD4HTTKMT2AKAT6A | |
| SCHEMBL4019477 | 0.90 | DRD4 (0.41) | KDM2BDRD4CYP2C9CYP2C19MCHR1 | |
| SCHEMBL4026436 | 0.88 | KDM2B (0.42) | KDM2BL3MBTL1HTTKMT2AKAT6A | |
| SCHEMBL4022391 | 0.87 | KDM2B (0.37) | KDM2BL3MBTL1DRD4HTTKMT2A | |
| SCHEMBL4022390 | 0.87 | KDM2B (0.37) | KDM2BL3MBTL1DRD4HTTKMT2A | |
| SCHEMBL13721097 | 0.87 | KDM2B (0.37) | KDM2BL3MBTL1DRD4HTTKMT2A | |
| SCHEMBL4021154 | 0.84 | KDM4E (0.34) | KDM2BL3MBTL1GSK3BKMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | claimed |
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | KDM2B 3090/4885L3MBTL1 3696/4885GSK3B 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.